JP4456918B2 - Wrinkle improving agent - Google Patents
Wrinkle improving agent Download PDFInfo
- Publication number
- JP4456918B2 JP4456918B2 JP2004115031A JP2004115031A JP4456918B2 JP 4456918 B2 JP4456918 B2 JP 4456918B2 JP 2004115031 A JP2004115031 A JP 2004115031A JP 2004115031 A JP2004115031 A JP 2004115031A JP 4456918 B2 JP4456918 B2 JP 4456918B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- wrinkle
- wrinkles
- decan
- tricyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
本発明は、老化に伴い、特に露光部位に発生するシワの改善効果に優れ、皮膚を皮膚科学的および美容的に健やかな状態に保つ効果を有する７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンを含有するシワ改善剤に関する。 The present invention has an effect of improving wrinkles generated particularly in exposed areas with aging, and has an effect of keeping the skin in a dermatological and cosmetically healthy state, 7,10,10-trimethyl-3-oxa- The present invention relates to a wrinkle improving agent containing 5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one.
ヒトをはじめとするすべての生物の臓器は、誕生して成長した後、加齢と伴に徐々に衰え、やがて機能停止し、機能停止した部分がある一定以上になると死に至る。その機能が徐々に衰えて行く状態を老化と呼んでいる。皮膚は、まわりの環境から直接影響を受けており、生体内部の環境を維持する重要な機能を持っているため全てが機能停止に至ることはあまりないが、シワ、シミ、くすみ、タルミなど老化徴候が顕在化しやすい臓器であり、日光に暴露される露光部位では特に顕著である。 Organs of all living organisms including humans are born and grow, then gradually decline with age, eventually stop functioning, and die when a certain part of the function is stopped. A state in which the function gradually declines is called aging. The skin is directly affected by the surrounding environment, and since it has an important function to maintain the environment inside the living body, it is unlikely that everything will stop functioning, but aging such as wrinkles, spots, dullness, tarmi, etc. This is an organ in which signs are easily manifested, and is particularly prominent in exposed areas exposed to sunlight.
皮膚の老化が進行すると、酸化ストレスなどの刺激に対する防御が弱まり、皮膚内部環境を乱す原因となり、さらに老化を進める。特に、露光部位では紫外線照射などが原因となる強い酸化ストレスに常に曝されていることから、老化の進行が顕著である。このような皮膚の変化を光老化と呼んでおり、そのような皮膚では、表皮が肥厚し、真皮では大多数を占める構成成分であるコラーゲンが減少することにより皮膚表面でシワが深く大きくなるなど美容上も好ましくない状態となる。 As skin aging progresses, defense against stimuli such as oxidative stress is weakened, causing the internal environment of the skin to be disturbed and further aging. In particular, since the exposed part is constantly exposed to strong oxidative stress caused by ultraviolet irradiation or the like, the progress of aging is remarkable. Such skin changes are called photoaging. In such skin, the epidermis is thickened, and the collagen, which is a major component in the dermis, decreases, causing wrinkles deeper and larger on the skin surface. This is also unfavorable for cosmetic purposes.
光老化が進行した結果生じるシワに対して改善効果を有する物質として、米国ではレチノイン酸が処方箋薬として用いられているが、副作用が強く安全性にも問題があるため、我が国では承認に至っていない。また、体内に吸収された後レチノイン酸に転換され効果を発揮すると言われているレチノール（ビタミンＡ）や抗酸化およびコラーゲン合成促進効果を持つアスコルビン酸（ビタミンＣ）、抗酸化効果の強いトコフェロール（ビタミンＥ）などシワ改善物質として提案されているが（例えば、特許文献１、特許文献２参照）、これらは十分に満足する効果が得られない欠点があった。したがって、これまでにシワを改善する物質として、十分に満足する効果を有し、安全性も有するものはなかった。 In the United States, retinoic acid is used as a prescription drug as a substance that has an improvement effect on wrinkles caused by the progress of photoaging, but it has not been approved in Japan because of its side effects and safety issues. . In addition, retinol (vitamin A), which is said to be converted into retinoic acid after being absorbed into the body and exert its effect, ascorbic acid (vitamin C) having an antioxidant and collagen synthesis promoting effect, and tocopherol having a strong antioxidant effect ( Vitamin E) and the like have been proposed as wrinkle-improving substances (see, for example, Patent Document 1 and Patent Document 2). Therefore, there has not been a substance that has a sufficiently satisfactory effect and safety as a substance for improving wrinkles so far.
本発明の目的は、老化により、特に露光部位で顕著に顕在化するシワの改善効果に優れ、美容的にも健やかな皮膚に保つ効果に優れた７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンを配合することを特徴とするシワ改善剤を提供することにある。 The object of the present invention is 7,10,10-trimethyl-3-oxa-, which is excellent in the effect of improving wrinkles that are noticeably manifested in aging due to aging, and excellent in the effect of maintaining cosmetically healthy skin. An object of the present invention is to provide a wrinkle improving agent characterized by blending 5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one.
本発明者らは、上記事情に鑑み、鋭意研究を行った結果、次のシワ改善剤が老化により、特に露光部位で顕著に出現するシワを改善し、美容的にも皮膚を健やかに保つ効果および安全性に優れることを確認して本発明を完成するに至った。すなわち、本発明は、下記化学式（１）
本発明は、加齢に伴い特に露光部位に発生するシワの改善効果に優れ、皮膚を皮膚科学的および美容的に健やかな状態に保つシワ改善剤を提供することができる。 INDUSTRIAL APPLICABILITY The present invention can provide a wrinkle improving agent that is excellent in improving wrinkles that occur particularly in exposed areas with aging and that keeps the skin in a dermatological and cosmetically healthy state.
以下、本発明の実施の形態を詳述する。７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンは、既知化合物であり、カンファーを出発原料として、カルボニル基のα位のニトロソ化、還元、炭酸ジエチルとの反応により用意に合成することができる。 Hereinafter, embodiments of the present invention will be described in detail. 7,10,10-Trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one is a known compound, which uses camphor as a starting material and has a carbonyl group. It can be easily synthesized by α-nitrosation, reduction, and reaction with diethyl carbonate.
本発明で用いられる７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンには立体異性体が存在するが、全ての異性体及びそれらの混合物のいずれでもシワの改善効果に優れる。 There are stereoisomers in 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one used in the present invention. Any of these isomers and mixtures thereof are excellent in wrinkle improvement effect.
７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンの配合量は、シワ改善剤の総量を基準としてそれぞれ０．００１〜１０．０質量％（以下、単に％と記する）が好ましい。７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンの配合量が０．００１％未満では本発明の目的とする効果が十分に得られない場合があり、配合量が１０．０％を越えても、その増加分に見合った効果の向上は望めない場合があり、また使用時の感触が悪くなり製剤化上支障をきたす傾向があるため好ましくない。 The blending amount of 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one was 0. 0% based on the total amount of wrinkle improver. 001 to 10.0% by mass (hereinafter simply referred to as%) is preferable. When the amount of 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one is less than 0.001%, the object of the present invention is achieved. The effect may not be sufficiently obtained, and even if the blending amount exceeds 10.0%, it may not be possible to improve the effect commensurate with the increased amount. Since it tends to cause trouble, it is not preferable.
本発明のシワ改善剤は、皮膚化粧料や外用剤として医薬品や入浴剤等に適用でき、剤型としては、例えばローション類、乳液類、クリーム類、パック類等とすることができる。尚、本発明のシワ改善剤には上記の他に色素、香料、防腐剤、界面活性剤、顔料、抗酸化剤等を本発明の目的を達成する範囲内で適宜配合することができる。 The wrinkle improving agent of the present invention can be applied as a skin cosmetic or an external preparation to pharmaceuticals, bathing agents, etc., and the dosage form can be, for example, lotions, emulsions, creams, packs and the like. In addition to the above, a coloring matter, a fragrance, a preservative, a surfactant, a pigment, an antioxidant and the like can be appropriately blended with the wrinkle improving agent of the present invention within a range that achieves the object of the present invention.
以下、実施例及び比較例に基づいて本発明を詳説する。 Hereinafter, the present invention will be described in detail based on examples and comparative examples.
実施例１（７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オン配合シワ改善剤）
７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンを配合したシワ改善剤を、光老化させた皮膚に適用し、そのシワ改善効果を次の試験方法により調べた。
Example 1 (7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one compounding wrinkle improving agent)
A wrinkle improving agent containing 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one was applied to photoaged skin. The wrinkle improvement effect was examined by the following test method.
（試験方法）
１． 実験動物
試験開始時１０週齢のヘアレスマウス１群１０匹を用いた。
(Test method)
1. Experimental animals One group of 10 hairless mice aged 10 weeks at the start of the test was used.
２． シワ改善効果の測定
２−１．光老化条件
光老化は、ＵＶＡとＵＶＢを１日１回、週５回、８週間照射することで誘発させた。照射量は、ＵＶＡが２０Ｊ／ｃｍ２、２５Ｊ／ｃｍ２、３０Ｊ／ｃｍ２、ＵＶＢが２０ｍＪ／ｃｍ２、３０ｍＪ／ｃｍ２、４０ｍＪ／ｃｍ２と、１週ごとに照射量を増量し、３週目以降は最大量を照射した。
2. 2. Measurement of wrinkle improvement effect 2-1. Photoaging conditions Photoaging was induced by irradiating UVA and UVB once a day, 5 times a week for 8 weeks. Irradiation dose, UVA is increased with 20J / cm 2, 25J / cm 2, 30J / cm 2, UVB is 20mJ / cm 2, 30mJ / cm 2, 40mJ / cm 2, an irradiation amount for each 1 week, 3 After week, the maximum dose was irradiated.
２−２．シワ改善効果の評価方法
シワ改善効果はシワスコアと表皮厚により評価した。シワスコアは、Ｂｉｓｓｅｔｔらの方法（Ｐｈｏｔｏｃｈｅｍ．Ｐｈｏｔｏｂｉｏｌ．４６：３６７−３７８、１９８７）に従って採点した。すなわち、シワの大きさおよび深さを肉眼で総合的に評価し、「大きく深いシワが確認できる」を３、「シワが確認できる」を２、「シワが確認できない」を１、「正常なキメが観察される」を０の４段階で採点した。表皮厚の測定は、全層皮膚を採取して定法に従って皮膚切片標本を作製したのちヘマトキシリン・エオシン染色を施し、表皮の厚さを画像解析ソフト（マイクロアナライザー、日本ポラデジタル社製）で測定した。
2-2. Evaluation method of wrinkle improvement effect The wrinkle improvement effect was evaluated by the wrinkle score and skin thickness. The wrinkle score was scored according to the method of Bissett et al. (Photochem. Photobiol. 46: 367-378, 1987). That is, the size and depth of the wrinkle are comprehensively evaluated with the naked eye, 3 indicating that “a large and deep wrinkle can be confirmed”, 2 indicating “a wrinkle can be confirmed”, 1 indicating “a wrinkle cannot be confirmed”, and “normal” “The texture is observed” was scored on a scale of 0. The skin thickness was measured by collecting the skin of all layers and preparing a skin slice sample according to a standard method, then staining with hematoxylin and eosin, and measuring the thickness of the epidermis with image analysis software (Microanalyzer, manufactured by Pola Digital Japan). .
２−３．試料と操作
５０％エタノール水溶液（基剤）に、７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンを１．０％配合した試料を調製した（実施例１）。また基剤のみの試料を比較例１とした。まず、これら試料０．１ｍＬをヘアレスマウスの背部皮膚（直径約２．５ｃｍ）に１日１回、１週間に５回の頻度で、ＵＶ照射開始後５週目から照射終了後４週目まで塗布した。そして、塗布終了後にシワスコアを採点し、屠殺後、皮膚を採取し表皮厚を測定した。シワスコアと表皮厚ともに、基剤（比較例１）塗布群を対照として比較した。
2-3. Sample and Operation To a 50% aqueous ethanol solution (base), 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one was added. A sample containing 0% was prepared (Example 1). A sample containing only the base was used as Comparative Example 1. First, 0.1 mL of these samples were applied to the back skin of a hairless mouse (diameter: about 2.5 cm) once a day at a frequency of 5 times a week from the fifth week after the start of UV irradiation to the fourth week after the end of irradiation Applied. And after completion | finish of application | coating, the wrinkle score was scored, after slaughtering, the skin was extract | collected and epidermis thickness was measured. Both the wrinkle score and the skin thickness were compared using the base (Comparative Example 1) application group as a control.
（シワスコア評価結果）
−−−−−−−−−−−−−−−−−−−−−−−−−−
群 シワスコア値（値は平均値±ＳＥ）
−−−−−−−−−−−−−−−−−−−−−−−−−−
実施例１塗布群 ２．２０ ± ０．１１
比較例１塗布群 ２．５５ ± ０．１１
−−−−−−−−−−−−−−−−−−−−−−−−−−
(Wrinkle score evaluation result)
-------------------------
Group Wrinkle score (value is mean ± SE)
-------------------------
Example 1 application group 2.20 ± 0.11
Comparative Example 1 application group 2.55 ± 0.11
-------------------------
実施例１のシワ改善剤塗布群では、比較例１塗布群と比較して有意に低いシワスコア値を示し（ｐ＜０．０５）、光老化により誘発したシワに対し、７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンが有効であることが示された。 The wrinkle improving agent application group of Example 1 showed a significantly lower wrinkle score value compared to the Comparative Example 1 application group (p <0.05), and 7,10,10− for wrinkles induced by photoaging. Trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one has been shown to be effective.
（表皮厚測定結果）
−−−−−−−−−−−−−−−−−−−−−−−−−−
群 表皮厚（μｍ、値は平均値±ＳＥ）
−−−−−−−−−−−−−−−−−−−−−−−−−−
実施例１塗布群 ３４．６２ ± ４．７４
比較例１塗布群 ４１．１６ ± ２．６０
−−−−−−−−−−−−−−−−−−−−−−−−−−
(Skin thickness measurement result)
-------------------------
Group Skin thickness (μm, values are mean ± SE)
-------------------------
Example 1 application group 34.62 ± 4.74
Comparative Example 1 application group 41.16 ± 2.60
-------------------------
実施例１のシワ改善剤塗布群では、比較例１塗布群と比較して有意に薄い表皮厚を示し（ｐ＜０．０５）、光老化により肥厚する表皮に対し、７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンが肥厚を軽減する効果を有することが示された。尚、レチノイン酸を本試験系に適用した場合、シワスコアおよびコラーゲン含有量には有効であるが、表皮厚に関しては肥厚を増進する方向に働き、この作用が安全性を問題視する一要因となっていた。それに比べ、７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンにはそのような作用もなく、通常の安全性試験においても何等問題は無かった。 In the wrinkle improving agent application group of Example 1, the skin thickness is significantly thinner than that in the Comparative Example 1 application group (p <0.05), and 7, 10, 10− for the epidermis thickened by photoaging. Trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one has been shown to have an effect of reducing thickening. When retinoic acid is applied to this test system, it is effective for the wrinkle score and collagen content, but the skin thickness works in the direction of increasing thickening, and this action is one factor that raises safety concerns. It was. In contrast, 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one has no such effect and is usually safe. There were no problems in the test.
以上の結果から、実施例１の７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンを配合したシワ改善剤が、比較例１と比較して明らかに、光老化によるシワを改善する効果を有することが示された。 From the above results, the wrinkle improving agent blended with 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one of Example 1 is obtained. It was clearly shown as compared with Comparative Example 1 that it has an effect of improving wrinkles due to photoaging.
実施例２、比較例２（スキンローション）
下記組成のスキンローション（実施例２、比較例２）を下記の調製法に従って調製し、それを試料として以下に従ってシワ改善効果を評価した。
５名の目尻にシワのある健常人（女性、４４〜５５歳）を被検者として、実施例２及び比較例２のスキンローションそれぞれを、左右のどちらかに決めて、朝洗顔後、及び夕方入浴後の１日２回、２ヵ月間（６０日）連続で目尻のシワの部分（各試料ごとに目尻を中心に約４ｃｍ２、２×２ｃｍ）に約０．２ｍＬずつ塗布してもらった。そして最終塗布後に左右の目尻部分の皮膚（シワ）の状態に関しアンケートに答えてもらった。
Example 2, Comparative Example 2 (skin lotion)
Skin lotions (Example 2, Comparative Example 2) having the following composition were prepared according to the following preparation method, and the wrinkle improvement effect was evaluated according to the following using the samples as samples.
Five healthy subjects with wrinkles at the corner of their eyes (female, 44-55 years old) were used as subjects, and the skin lotions of Example 2 and Comparative Example 2 were determined to be either left or right, after washing in the morning, and Twice a day after bathing in the evening for 2 months (60 days), apply about 0.2 mL of wrinkles on the corner of the eye (about 4 cm 2 , 2 x 2 cm centered on the corner of each eye for each sample). It was. Then, after the final application, they were asked to answer a questionnaire regarding the condition of the skin (wrinkles) on the left and right eye corners.
（組成）
原 料 成 分 配合量（％）
Ａ成分
（１）オリーブ油 １０．０
（２）ミリスチン酸イソプロピル １．０
（３）モノラウリン酸
ポリオキシエチレン（２０）ソルビタン ０．５
（４）プロピレングリコール １．０
（５）グリセリン ２．０
Ｂ成分
（６）メチルパラベン ０．１
（７）エタノール ７．０
（８）精製水 残 量
Ｃ成分
（９）７，１０，１０−トリメチル−３−オキサ− ２．０（実施例２）
５−アザ−トリシクロ[５．２．１．０２，６] または
デカン−４−オン ０ （比較例２）
(composition)
Ingredients Component Amount (%)
Component A (1) Olive oil 10.0
(2) Isopropyl myristate 1.0
(3) Monolauric acid polyoxyethylene (20) sorbitan 0.5
(4) Propylene glycol 1.0
(5) Glycerin 2.0
Component B (6) Methylparaben 0.1
(7) Ethanol 7.0
(8) Purified water remaining amount C component (9) 7,10,10-trimethyl-3-oxa-2.0 (Example 2)
5-aza-tricyclo [5.2.1.0 2,6 ] or decan-4-one 0 (Comparative Example 2)
（製法）
Ｃ成分の７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンをＢ成分に添加して均一に溶解した後、Ａ成分を添加して混合撹拌分散し、次いで容器に充填した。使用時には内容物を均一に振盪分散して使用した。
(Manufacturing method)
After C component 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one was added to component B and uniformly dissolved, Component A was added, mixed and dispersed with stirring, and then filled into a container. During use, the contents were uniformly shaken and dispersed.
アンケート結果をもとに、皮膚（シワ）の状態に関する各項目において、比較例２より実施例２のスキンローションのほうが有効であると回答した人数を以下に示す。 Based on the questionnaire results, the number of people who answered that the skin lotion of Example 2 is more effective than Comparative Example 2 for each item related to the state of skin (wrinkles) is shown below.
−−−−−−−−−−−−−−−−−−−
項目 人数（名）
−−−−−−−−−−−−−−−−−−−
シワが目立たなくなった ５
皮膚が柔らかくなった ４
皮膚にハリがでた ５
皮膚につやがでた ３
皮膚があかるくなった ３
−−−−−−−−−−−−−−−−−−−
-------------------
Item Number of people
-------------------
Wrinkles are less noticeable 5
The skin became soft 4
The skin got firmer 5
Shining on the skin 3
My skin became moist 3
-------------------
本試験結果から実施例２のスキンローションは、比較例２と比較して明らかにシワを改善しており、さらに、光老化により悪化する柔軟性や色調までもが改善されたことが分かる。また、本発明のスキンローションによる刺激や痒み等の皮膚の異常は認められなかった。 From this test result, it can be seen that the skin lotion of Example 2 clearly improved the wrinkles as compared with Comparative Example 2, and further improved the flexibility and color tone deteriorated by photoaging. In addition, skin abnormalities such as irritation and itching due to the skin lotion of the present invention were not observed.
実施例３（スキンクリーム）
７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンを配合したスキンクリームを下記組成と製法にて調製した。
Example 3 (skin cream)
A skin cream blended with 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one was prepared by the following composition and production method.
（組成）
原 料 成 分 配合量（％）
Ａ成分
（１）密ロウ ２．０
（２）ステアリン酸 ５．０
（３）ステアリルアルコール ５．０
（４）還元ラノリン ２．０
（５）スクワレン ２０．０
（６）モノステアレートソルビタン ３．０
（７）モノステアレート
ポリオキシエチレン（２０）ソルビタン ３．０
（８）プロピレングリコ−ル ５．０
Ｂ成分
（９）メチルパラベン ０．２
（１０）精製水 残 量
Ｃ成分
（１１）７，１０，１０−トリメチル−３−オキサ− ２．０
５−アザ−トリシクロ[５．２．１．０２，６]
デカン−４−オン
(composition)
Ingredients Component Amount (%)
A component (1) dense wax 2.0
(2) Stearic acid 5.0
(3) Stearyl alcohol 5.0
(4) Reduced lanolin 2.0
(5) Squalene 20.0
(6) Monostearate sorbitan 3.0
(7) Monostearate Polyoxyethylene (20) Sorbitan 3.0
(8) Propylene glycol 5.0
Component B (9) Methylparaben 0.2
(10) Purified water remaining amount C component (11) 7,10,10-trimethyl-3-oxa-2.0
5-Aza-tricyclo [5.2.1.0 2,6 ]
Decan-4-one
（製法）
Ｃ成分の７，１０，１０−トリメチル−３−オキサ−５−アザ−トリシクロ[５．２．１．０２，６]デカン−４−オンをＢ成分に配合した後、Ａ，Ｂ成分を各々８０℃に加熱溶解し、混合して撹拌しつつ、３０℃まで冷却してスキンクリ−ムを調製した。
(Manufacturing method)
C component 7,10,10-trimethyl-3-oxa-5-aza-tricyclo [5.2.1.0 2,6 ] decan-4-one was added to component B, and then components A and B were added. Each was heated and dissolved at 80 ° C., mixed and stirred, and cooled to 30 ° C. to prepare a skin cream.
事前アンケートで目尻のシワを肌悩みとして挙げた２０名の健常人（女性，５０〜５５歳）に、前記スキンクリームを１週間以上使用してもらった。シワの状態に関して下記項
目のアンケート調査を行い、各項目ごとに使用前と比較して使用後にそう思うと回答した人の人数を以下に示した。
Twenty healthy persons (women, 50-55 years old) who listed wrinkles in the corners of their eyes as a skin problem in a preliminary questionnaire were asked to use the skin cream for over a week. The following items were surveyed on wrinkle conditions, and the number of people who answered that they thought so after using each item compared to before using was shown below.
−−−−−−−−−−−−−−−−−−−
項目 人数（名）
−−−−−−−−−−−−−−−−−−−
シワが目立たなくなった １８
シワの大きさが減少した １６
シワの数が減少した ５
シワが増えた ０
−−−−−−−−−−−−−−−−−−−
-------------------
Item Number of people
-------------------
Wrinkles are less noticeable 18
Wrinkle size decreased 16
Number of wrinkles decreased 5
Increased wrinkles 0
-------------------
本試験結果から実施例３のスキンクリームは、使用前と比較してシワが目立たなくなったと実感しているヒトがほぼ全員で、その要因としてシワの数よりもシワの大きさを軽減することで、光老化によるシワを改善したことが分かる。また、本発明のスキンクリームによる刺激や痒み等の皮膚の異常は認められなかった。 From this test result, the skin cream of Example 3 is almost all humans who feel that wrinkles are less noticeable than before use, and the factor is that the size of wrinkles is reduced rather than the number of wrinkles. It can be seen that wrinkles due to photoaging were improved. In addition, skin abnormalities such as irritation and itching due to the skin cream of the present invention were not observed.
皮膚化粧料や外用剤として医薬品や入浴剤等に適用でき、剤型的には例えばロ−ション類、乳液類、クリ−ム類、パック類等とすることができ、皮膚の美容の面から非常に有用である。
It can be applied to skin care cosmetics and external preparations, such as pharmaceuticals and baths, and can be formulated into lotions, milks, creams, packs, etc. Very useful.
Claims (1)
The following chemical formula (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004115031A JP4456918B2 (en) | 2004-04-09 | 2004-04-09 | Wrinkle improving agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004115031A JP4456918B2 (en) | 2004-04-09 | 2004-04-09 | Wrinkle improving agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005298383A JP2005298383A (en) | 2005-10-27 |
| JP4456918B2 true JP4456918B2 (en) | 2010-04-28 |
Family
ID=35330364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004115031A Expired - Fee Related JP4456918B2 (en) | 2004-04-09 | 2004-04-09 | Wrinkle improving agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4456918B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6614448B2 (en) * | 2016-03-31 | 2019-12-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | Anti-photoaging agent |
-
2004
- 2004-04-09 JP JP2004115031A patent/JP4456918B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005298383A (en) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4584991B2 (en) | Skin cosmetics and wrinkle improvers | |
| CA2907495C (en) | Antioxidant compositions and methods of using the same | |
| RU2712152C1 (en) | Compositions for reducing irritation by synergetic action of taurine and aloe and related methods | |
| BRPI0721698A2 (en) | Useful gel for the release of cosmetic active ingredients | |
| JP2002363058A (en) | Use of composition containing at least one kind of chelating agent for increasing tolerance limit of sensitive skin or nonresistive skin | |
| JP4567732B2 (en) | Skin cosmetics and wrinkle improvers | |
| JP4579564B2 (en) | Wrinkle improving agent | |
| JP4934280B2 (en) | Wrinkle improving agent | |
| JP4456918B2 (en) | Wrinkle improving agent | |
| JP4488933B2 (en) | Wrinkle improving agent and external composition for skin | |
| JPH0437044B2 (en) | ||
| JPH06321754A (en) | Skin beautifying agent | |
| JP3826132B2 (en) | Wrinkle improving agent | |
| JP2006248953A (en) | Wrinkle ameliorating agent and external composition for skin | |
| JP5244284B2 (en) | Wrinkle improving agent | |
| JP4359197B2 (en) | Wrinkle improving agent and skin cosmetic | |
| JPH0761919A (en) | Bautifying agent | |
| JP5768114B2 (en) | Method for producing an external preparation for aging | |
| Somwanshi et al. | Cosmetic Science | |
| JP4359235B2 (en) | Wrinkle improving agent and skin cosmetic | |
| JP2006232747A (en) | Ameliorant for wrinkle and skin cosmetic | |
| WO2010013423A1 (en) | External preparation for skin, and wrinkle-repairing agent | |
| JP2022037267A (en) | Topical preparation for preventing and/or improving xanthoderma | |
| JPH06321751A (en) | Skin beautifying agent | |
| JPH06321753A (en) | Skin beautifying agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060822 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080201 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090623 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100202 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100208 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 4456918 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140212 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |